CPC G09B 19/00 (2013.01) [A61B 5/0205 (2013.01); A61B 5/0531 (2013.01); A61B 5/0806 (2013.01); A61B 5/14551 (2013.01); A61B 5/165 (2013.01); A61B 5/486 (2013.01); A61B 5/4815 (2013.01); A61B 5/4818 (2013.01); A61B 5/4836 (2013.01); A61B 5/4839 (2013.01); A61B 5/4842 (2013.01); A61B 5/4848 (2013.01); A61B 5/7267 (2013.01); A61B 5/7275 (2013.01); A61B 5/7475 (2013.01); A61K 31/4045 (2013.01); A61M 16/0003 (2014.02); A61M 16/024 (2017.08); A61M 16/026 (2017.08); G06N 3/08 (2013.01); G06N 5/02 (2013.01); G06N 20/00 (2019.01); G16H 10/20 (2018.01); G16H 10/60 (2018.01); G16H 20/00 (2018.01); G16H 20/10 (2018.01); G16H 20/30 (2018.01); G16H 20/60 (2018.01); G16H 40/67 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01); G16H 50/70 (2018.01); A61B 5/02405 (2013.01); A61B 5/1118 (2013.01); A61B 5/4806 (2013.01); A61B 2560/0242 (2013.01); A61B 2560/0257 (2013.01); A61B 2562/0219 (2013.01); A61M 2205/3303 (2013.01); A61M 2205/3584 (2013.01); A61M 2205/502 (2013.01)] | 12 Claims |
1. A method of automatically and dynamically titrating treatment for altitude-induced Central Sleep Apnea (CSA) for a person using a wearable device structured to be worn on a body of the person and having a processor apparatus, comprising:
for each of a number of periods of sleep of the person, determining in the wearable device a number of Sleep-Disordered Breathing (SDB) severity values, each SDB severity value of the number of SDB severity values being based at least in part upon a corresponding effective altitude value and a corresponding dosage of a CSA treatment;
automatically determining in the wearable device a current effective altitude of the person;
determining in the wearable device based at least in part upon at least a subset of the number of Sleep-Disordered Breathing (SDB) severity values and the current effective altitude, a preferred dosage of the CSA treatment at which a likely SDB severity value is no greater than a predetermined SDB severity value; and
generating an output from the wearable device indicating a recommended treatment for CSA at the preferred dosage of the CSA treatment.
|